MBX Biosciences (MBX) news
Recent news
Trading halt: Aztr (AMEX) - Regulatory concern
On October 13, 2026, trading for Aztr (AMEX) was temporarily suspended amid regulatory concerns, according to reports. While no official statement has been issued by the New York Stock Exchange, the halt has raised questions among investors about the company’s compliance status and operational…
AInvest Wire · 7h agoMBX Biosciences, Inc.: Stifel raises target price to $84 from $70
AInvest Wire · 1d agoMBX Biosciences announces appointment of Jeff Held as chief legal officer
MBX Biosciences, a clinical-stage biopharmaceutical company focused on the development of novel peptide therapeutics for endocrine and metabolic disorders, has announced appointment of Jeff Held as Chief Legal Officer. Held brings extensive legal and operational experience from his career in the…
AInvest Wire · Sep 8, 2026Truist Securities raises target price to $88 from $70 for MBX Biosciences, Inc.
Truist Securities has revised its price target for MBX Biosciences, Inc. (MBX), raising it to $88 from the previous $70, while maintaining an Overweight rating on the stock. This adjustment follows an updated financial model based on the company’s second-quarter performance report. The increased…
AInvest Wire · Aug 10, 2026MBX Biosciences shares down 10% after the bell; announces executive leadership transition to support the company’s next phase of growth
MBX Biosciences has completed an immediate executive leadership transition, with Kent Hawryluk stepping down as president, CEO, and board member, and Steve Hoelter appointed as new chairman and CEO to support the company’s next phase of growth, with the changes taking effect immediately, as…
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.